Company Overview of Cadila Pharmaceuticals Limited
Cadila Pharmaceuticals Limited operates as a pharmaceutical company worldwide. The company develops branded and generic formulations for humans and animals; active pharmaceutical ingredients; biotechnology products and diagnostic kits; and plant tissue cultures. It also offers contract research and contract manufacturing services. The company offers its products for various therapeutic areas, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives, antibiotics, respiratory, anti diabetics, immunologicals, antipyretics, anthelmintics, anti-hypertensives, anti-inflammatory preparations, antibacterials, vitamins, iron and protein tonics, and ophthalmology. It has a ...
Key Executives for Cadila Pharmaceuticals Limited
Chairman and Managing Director
Compensation as of Fiscal Year 2016.
Cadila Pharmaceuticals Limited Key Developments
Oncology Venture and Cadila Pharmaceuticals Partner in Anticancer Product Development
Sep 20 16
Oncology Venture Sweden AB and Cadila Pharmaceuticals Ltd. will develop the anticancer product LiPlaCis in combination with its drug response predictor - DRP, under a co-development agreement. The partners plan to evaluate the LiPlaCis efficacy in several different indications and conduct clinical trials in 310 cancer patients to collect data for future marketing approval of the product in the US, Europe and India. To this end, Cadila will initiate four Phase II and one Phase III studies over a period of three years, while Oncology Venture will take responsibility for the manufacturing and will provide the product. The commercialisation rights in India, Russia, Africa and South East Asia will be held by Cadila. Oncology Venture may commercialise the product in America, Europe, China and rest of the world. Upon successful development, Oncology Venture and Cadila may decide to market the drug on their own in their respective territories or out-license or sell it to a third party.
Medical Prognosis Institute A/S Enters Co-Development Agreement with Cadila Pharmaceuticals Ltd
Sep 20 16
Medical Prognosis Institute A/S entered a co-development agreement with Cadila Pharmaceuticals Ltd. to develop the anticancer product LiPlaCis® in combination with its Drug Response Predictor DRPTM. LiPlaCis® is the lead product in Oncology Ventures pipeline, and the agreement with Cadila secures the in-kind funding of several phase 2 and phase 3 trials using the Drug Response Predictor, DRPTM. Cadila Pharmaceuticals is one of the larger privately held pharmaceutical companies in India. In accordance with the agreement more than 1 250 metastatic breast cancer patients will be screened by the use of the LiPlaCis-DRPTM of to identify 250 patients with high likelihood to respond to LiPlaCis treatment and perform a randomized phase 3 trial in these 250 patients comparing standard therapy with LiPlaCis. Through Cadilas strong network and Cadilas CRO four (4) clinical Phase 2 trials in 20 patients (out of 100 screened) with Head & Neck cancer, 20 prostate cancer patients (out of 100 screened), and 10 skin cancer patients and 10 esophagus cancer patients are planned. The two latter indications are in a high frequency sensitive to cisplatin - of which LiPlaCis® is an improved formulation - why the patients will not be screened.
Galenika Received Bids From 3 Companies
Aug 1 16
Galenika a.d. received bids for sale of 25% stake. Bidders include Cadila Pharmaceuticals Limited, EMS S.A., Frontier Pharma Limited, NPO Petrovax Pharm LLC. The bids will be opened on Friday, July 29, 2016, the ministry said in a statement. The bids will be ranked according to the number of jobs proposed and the plans for recapitalization of the company as the two most important criteria, the statement reads. The government will then announce the best bidder and it will have up to 90 days to negotiate a final deal with it.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|